A Destabilizing Domain Allows for Fast, Noninvasive, Conditional Control of Protein Abundance in the Mouse Eye - Implications for Ocular Gene Therapy

• Published in: Investigative ophthalmology & visual science 2018-10, Vol.59 (12), p.4909-4920
• Main Authors: Datta, Shyamtanu, Renwick, Marian, Chau, Viet Q, Zhang, Fang, Nettesheim, Emily R, Lipinski, Daniel M, Hulleman, John D
• Format: Article
• Language: English
• Subjects: Administration, Oral; Animals; Bacterial Proteins - metabolism; Blotting, Western; Chromatography, Liquid; Dependovirus; Electroretinography; Escherichia coli - enzymology; Folic Acid Antagonists - therapeutic use; Genetic Therapy; Genetic Vectors; Intravitreal Injections; Luminescent Agents - metabolism; Luminescent Proteins - metabolism; Mice; Mice, Inbred C57BL; Parvovirinae - genetics; Plasmids; Real-Time Polymerase Chain Reaction; Red Fluorescent Protein; Retina; Retina - drug effects; Retina - metabolism; Tandem Mass Spectrometry; Tetrahydrofolate Dehydrogenase - genetics; Tetrahydrofolate Dehydrogenase - metabolism; Trimethoprim - therapeutic use; Visual Acuity - physiology
• ISSN: 1552-5783; 0146-0404; 1552-5783
• DOI: 10.1167/iovs.18-24987

Temporal and reversible control of protein expression in vivo is a central goal for many gene therapies, especially for strategies involving proteins that are detrimental to physiology if constitutively expressed. Accordingly, we explored whether protein abundance in the mouse retina could be effectively controlled using a destabilizing Escherichia coli dihydrofolate reductase (DHFR) domain whose stability is dependent on the small molecule, trimethoprim (TMP). We intravitreally injected wild-type C57BL6/J mice with an adeno-associated vector (rAAV2/2[MAX]) constitutively expressing separate fluorescent reporters: DHFR fused to yellow fluorescent protein (DHFR.YFP) and mCherry. TMP or vehicle was administered to mice via oral gavage, drinking water, or eye drops. Ocular TMP levels post treatment were quantified by LC-MS/MS. Protein abundance was measured by fundus fluorescence imaging and western blotting. Visual acuity, response to light stimulus, retinal structure, and gene expression were evaluated after long-term (3 months) TMP treatment. Without TMP, DHFR.YFP was efficiently degraded in the retina. TMP achieved ocular concentrations of ∼13.6 μM (oral gavage), ∼331 nM (drinking water), and ∼636 nM (eye drops). Oral gavage and TMP eye drops stabilized DHFR.YFP as quickly as 6 hours, whereas continuous TMP drinking water could stabilize DHFR.YFP for ≥3 months. Stabilization was completely and repeatedly reversible following removal/addition of TMP in all regimens. Long-term TMP treatment had no impact on retina function/structure and had no effect on >99.9% of tested genes. This DHFR-based conditional system is a rapid, efficient, and reversible tool to effectively control protein expression in the retina.